4//SEC Filing
HUNT RONALD 4
Accession 0000950170-24-095094
CIK 0001659323other
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 9:00 AM ET
Size
23.1 KB
Accession
0000950170-24-095094
Insider Transaction Report
Form 4
HUNT RONALD
Director
Transactions
- Exercise/Conversion
Subscription Rights (right to buy)
2024-08-06−364,906→ 0 total(indirect: By New Leaf Ventures III, L.P.)Exercise: $0.61From: 2024-07-22Exp: 2024-08-06→ Units - Exercise/Conversion
Subscription Rights (right to buy)
2024-08-06−130,962→ 0 total(indirect: By New Leaf Biopharma Opportunities II, L.P.)Exercise: $0.61From: 2024-07-22Exp: 2024-08-06→ Units - Exercise/Conversion
Warrants (right to buy)
2024-08-06+65,481→ 65,481 total(indirect: By New Leaf Biopharma Opportunities II, L.P.)Exercise: $1.21From: 2024-08-09Exp: 2025-08-09→ Ordinary Shares (32,740 underlying) - Exercise/Conversion
Ordinary Shares
2024-08-06+182,453→ 253,898 total(indirect: By New Leaf Ventures III, L.P.) - Exercise/Conversion
Ordinary Shares
2024-08-06+65,481→ 91,122 total(indirect: By New Leaf Biopharma Opportunities II, L.P.) - Exercise/Conversion
Warrants (right to buy)
2024-08-06+182,453→ 182,453 total(indirect: By New Leaf Ventures III, L.P.)Exercise: $1.21From: 2024-08-09Exp: 2025-08-09→ Ordinary Shares (91,226 underlying) - Exercise/Conversion
Warrants (right to buy)
2024-08-06+182,453→ 182,453 total(indirect: By New Leaf Ventures III, L.P.)Exercise: $1.21From: 2024-08-09Exp: 2029-08-09→ Ordinary Shares (182,453 underlying) - Exercise/Conversion
Warrants (right to buy)
2024-08-06+65,481→ 65,481 total(indirect: By New Leaf Biopharma Opportunities II, L.P.)Exercise: $1.21From: 2024-08-09Exp: 2029-08-09→ Ordinary Shares (65,481 underlying)
Footnotes (6)
- [F1]The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, New Leaf Ventures III, L.P. ("NLV-III") purchased 182,453 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants").
- [F2]These shares are held directly by NLV-III. New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any.
- [F3]The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, New Leaf Biopharma Opportunities II, L.P. ("NBPO-II") purchased 65,481 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants").
- [F4]These shares are held directly by NBPO-II. New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any.
- [F5]NLV-III validly exercised 364,906 subscription rights to acquire 182,453 units composed of (i) 182,453 ordinary shares, (ii) 182,453 1-year warrants and (iii) 182,453 5-year warrants.
- [F6]NBPO-II validly exercised 130,962 subscription rights to acquire 65,481 units composed of (i) 65,481 ordinary shares, (ii) 65,481 1-year warrants and (iii) 65,481 5-year warrants.
Documents
Issuer
Iterum Therapeutics plc
CIK 0001659323
Entity typeother
Related Parties
1- filerCIK 0001247851
Filing Metadata
- Form type
- 4
- Filed
- Aug 11, 8:00 PM ET
- Accepted
- Aug 12, 9:00 AM ET
- Size
- 23.1 KB